Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.32 |
| ▸ | PPM1B | O75688 | 2/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.31 |
| ▸ | PPP1CC | P36873 | 2/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509386 | 1.00 | CCR5 (0.37) | CCR5HSD11B1CHRM2CHRM1CHRM3 | |
| SCHEMBL4555290 | 0.85 | ADH1C (0.33) | HSD11B1 | |
| SCHEMBL4555291 | 0.85 | ADH1C (0.33) | HSD11B1 | |
| SCHEMBL509697 | 0.84 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL508874 | 0.84 | CCR5 (0.32) | CCR5HSD11B1 | |
| SCHEMBL508875 | 0.84 | CCR5 (0.32) | CCR5HSD11B1 | |
| SCHEMBL509698 | 0.84 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL3824368 | 0.83 | CCR5 (0.42) | CCR5HSD11B1GPR119NFKB1NFKB2 | |
| SCHEMBL510107 | 0.81 | HSD11B1 (0.44) | HSD11B1CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL510106 | 0.81 | HSD11B1 (0.44) | HSD11B1CHRM2CHRM1CHRM3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218713-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20210113571-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2021-04-22 | — | — | US | disclosed |
| US-20200281933-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2020-09-10 | — | — | US | disclosed |
| US-20200030335-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2020-01-30 | — | — | US | disclosed |
| US-20190175603-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2019-06-13 | — | — | US | disclosed |
| US-20180303842-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2018-10-25 | — | — | US | disclosed |
| US-20170266194-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| EP-2380874-B1 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2016-12-28 | — | — | EP | disclosed |
| US-20140256731-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2014-09-11 | — | — | US | disclosed |
| US-20130040954-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HONG KONG KING-FRIEND INDUSTRIAL COMPANY LTD. (CN) | 2013-02-14 | — | — | US | disclosed |
| US-8153689-B2 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2012-04-10 | — | — | US | disclosed |
| US-20120029072-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG | 2012-02-02 | — | — | US | disclosed |
| US-8071643-B2 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | NABRIVA THERAPEUTICS AG (AT) | 2011-12-06 | — | — | US | disclosed |
| EP-2380874-A2 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | Nabriva Therapeutics AG (AT) | 2011-10-26 | — | — | EP | disclosed |
| EP-2137143-B1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2011-09-07 | — | — | EP | disclosed |
| US-20100035987-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2010-02-11 | — | — | US | disclosed |
| EP-2137143-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | Nabriva Therapeutics AG (AT) | 2009-12-30 | — | — | EP | disclosed |
| US-20090118366-A1 | ORGANIC COMPOUNDS | NABRIVA THERAPEUTICS FORSCHUNGS GMBH (AT) | 2009-05-07 | — | — | US | disclosed |
| WO-2008113089-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | NABRIVA THERAPEUTICS AG (AT) | 2008-09-25 | — | — | WO | disclosed |
| EP-1972618-A1 | Pleuromutilin derivatives for the treatment of diseases mediated by microbes | Nabriva Therapeutics AG (AT) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200281933-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | CCR5 2044/4885HSD11B1 2388/4885CHRM2 2513/4885 |
| US-20140256731-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | CCR5 1740/4885HSD11B1 2573/4885CHRM2 2631/4885 |
| US-20090118366-A1 | ORGANIC COMPOUNDS | C5, C9, C1S | CCR5 149/4885HSD11B1 97/4885CHRM2 1164/4885 |
| US-20220218713-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | CCR5 2027/4885HSD11B1 2506/4885CHRM2 2799/4885 |
| US-20130040954-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | CCR5 1740/4885HSD11B1 2573/4885CHRM2 2631/4885 |
| US-20190175603-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | CCR5 2044/4885HSD11B1 2388/4885CHRM2 2513/4885 |
| US-20170266194-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HRH4, HRH2, CHRM1 | CCR5 439/4885HSD11B1 771/4885CHRM2 4/4885 |
| US-20100035987-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, FABP6, ALPI | CCR5 2442/4885HSD11B1 1969/4885CHRM2 3908/4885 |
| US-20200030335-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | HRH4, HRH2, CHRM1 | CCR5 439/4885HSD11B1 771/4885CHRM2 4/4885 |
| US-20210113571-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | CCR5 2027/4885HSD11B1 2506/4885CHRM2 2799/4885 |
| US-20180303842-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, PLEC, FABP6 | CCR5 2044/4885HSD11B1 2388/4885CHRM2 2513/4885 |
| US-20120029072-A1 | PLEUROMUTILIN DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY MICROBES | FABP2, FABP6, PLEC | CCR5 2564/4885HSD11B1 2245/4885CHRM2 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.